In this research study the investigators want to learn more about how a medication called tranexamic acid (TXA) could help reduce bleeding during Periacetabular Osteotomy (PAO) surgery. TXA is approved by the Food and Drug Administration (FDA) for the reduction of bleeding for many types of surgical procedures. TXA works by slowing the breakdown of blood clots and helps to prevent bleeding. From previous studies, TXA has been shown to effectively prevent bleeding in patients undergoing heart, spine and skull remodeling surgeries. As PAO surgery has been associated with significant blood loss when compared to other types of joint surgeries. In order to try and avoid bleeding that may lead to complications, different strategies can be used. In this research study the investigators want to learn more about how a medication called tranexamic acid (TXA) could help reduce bleeding during PAO surgery.
This prospective randomized placebo controlled double blind trial will enroll 80 adolescents and young adults undergoing elective peri-acetabular osteotomy (PAO). The primary aim is to determine if intravenous infusion of TXA during surgery is effective compared to standard care (no TXA) in decreasing blood loss (measured; and calculated) and blood transfusion (autologous and allogenic) perioperatively in adolescents and young adults presenting for PAO surgery. The rate of blood loss over time will be measured and compared between groups with adjustment for length of surgery (time; hours) and body weight (kg).
Age 13-35 years
Scheduled for primary unilateral PAO +/- arthroscopy
Hematologic disorder, thrombocytopenia (Platelet count <140,000/uL3)
Major hepatic, renal, or vascular disorder
Active Thromboembolic disorder
Color vision defect
Taking anticoagulants or antiplatelet drugs (heparin, warfarin, clopidogrel)
Ethical and/or religious objection to receiving blood products
Patients undergoing revision surgery
Patients undergoing combined PAO and other surgeries such as surgical dislocation, proximal femoral osteotomy
October 4, 2019
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: